Cagrilintide 10mg

Cagrilintide is an investigational, long-acting, injectable amylin analogue designed for weight management and type 2 diabetes treatment. Developed by Novo Nordisk, it acts by reducing appetite, increasing satiety, and slowing gastric emptying. Clinical trials have shown significant weight reduction (e.g., 9.7% in 26 weeks) and enhanced efficacy when paired with semaglutide (CagriSema).

Key Aspects of Cagrilintide:

• Combination Therapy (CagriSema): The combination of cagrilintide (2.4 mg) and semaglutide (2.4 mg) has demonstrated strong potential, with a 17.1% reduction in body weight observed in studies, often referred to as "CagriSema".

• Side Effects: Similar to GLP-1 receptor agonists, common side effects are gastrointestinal, including nausea (up to 50% of patients), vomiting, diarrhea, and constipation.

• Status: It is currently under investigation, often in combination with semaglutide for obesity and type 2 diabetes management. 

• Mechanism of Action: It is a synthetic amylin analog that acts as an agonist at amylin receptors (AMY1R, AMY2R, AMY3R) and the calcitonin receptor to promote weight loss through brain-mediated appetite regulation.
• Benefits:

   In addition to substantial weight loss, studies suggest it helps manage obesity and associated comorbidities

  .

Cagrilintide provides a distinct pathway from GLP-1 drugs, offering a complementary approach to appetite regulation. 

FDA Disclaimer: This product has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease. For research use only.